

For Immediate Release

**CENTERS FOR MEDICARE AND MEDICAID SERVICES  
FAVORABLY REVISE PAYMENT POLICIES FOR REMODULIN®**

Silver Spring, MD, November 2, 2004: United Therapeutics Corporation (NASDAQ: UTHR) announced today that the Centers for Medicare and Medicaid Services (CMS) has updated its payment policies relating to Remodulin. As a result, the under-reimbursement situation relating to certain Medicare patients on Remodulin during 2004 has now been favorably resolved.

CMS issued *CMS Manual System, Pub. 100-20 One-Time Notification, Transmittal 123* (the "Transmittal"), effective January 1, 2004, which requires the four regional Durable Medical Equipment Carriers (DMERCs) to use the payment limit established in January 2004 for the pricing of Remodulin. That payment limit is \$61.75 per milligram. The Transmittal also requires the DMERCs to retroactively adjust claims brought to their attention. A copy of the Transmittal is available at [http://www.cms.hhs.gov/manuals/pm\\_trans/R123OTN.pdf](http://www.cms.hhs.gov/manuals/pm_trans/R123OTN.pdf).

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique products.